دورية أكاديمية
Management of male obesity-related secondary hypogonadism: A clinical update.
| العنوان: | Management of male obesity-related secondary hypogonadism: A clinical update. |
|---|---|
| المؤلفون: | Shenoy MT; Department of Endocrinology, Sree Gokulam Medical College, and Research Foundation, Trivandrum 695607, Kerala, India., Mondal S; Department of Endocrinology, NRS Medical College and Hospital, Kolkata 700014, West Bengal, India., Fernandez CJ; Department of Endocrinology & Metabolism, Pilgrim Hospital, United Lincolnshire Hospitals NHS Trust, Boston PE21 9QS, United Kingdom., Pappachan JM; Department of Endocrinology and Metabolism, Lancashire Teaching Hospitals NHS Trust, Preston PR2 9HT, United Kingdom.; Faculty of Science, Manchester Metropolitan University, Manchester M15 6BH, United Kingdom.; Faculty of Biology, Medicine & Health, The University of Manchester, Manchester M13 9PL, United Kingdom. drpappachan@yahoo.co.in. |
| المصدر: | World journal of experimental medicine [World J Exp Med] 2024 Jun 20; Vol. 14 (2), pp. 93689. Date of Electronic Publication: 2024 Jun 20 (Print Publication: 2024). |
| نوع المنشور: | Journal Article; Review |
| اللغة: | English |
| بيانات الدورية: | Publisher: Baishideng Publishing Group Country of Publication: United States NLM ID: 101618808 Publication Model: eCollection Cited Medium: Print ISSN: 2220-315X (Print) Linking ISSN: 2220315X NLM ISO Abbreviation: World J Exp Med Subsets: PubMed not MEDLINE |
| أسماء مطبوعة: | Publication: 2014-: Pleasanton, CA : Baishideng Publishing Group Original Publication: Hong Kong, China : Baishideng Publishing Group Co., Limited |
| مستخلص: | The global obesity pandemic has resulted in a rise in the prevalence of male obesity-related secondary hypogonadism (MOSH) with emerging evidence on the role of testosterone therapy. We aim to provide an updated and practical approach towards its management. We did a comprehensive literature search across MEDLINE ( via PubMed), Scopus, and Google Scholar databases using the keywords "MOSH" OR "Obesity-related hypogonadism" OR "Testosterone replacement therapy" OR "Selective estrogen receptor modulator" OR "SERM" OR "Guidelines on male hypogonadism" as well as a manual search of references within the articles. A narrative review based on available evidence, recommendations and their practical implications was done. Although weight loss is the ideal therapeutic strategy for patients with MOSH, achievement of significant weight reduction is usually difficult with lifestyle changes alone in real-world practice. Therefore, androgen administration is often necessary in the management of hypogonadism in patients with MOSH which also improves many other comorbidities related to obesity. However, there is conflicting evidence for the appropriate use of testosterone replacement therapy (TRT), and it can also be associated with complications. This evidence-based review updates the available evidence including the very recently published results of the TRAVERSE trial and provides comprehensive clinical practice pearls for the management of patients with MOSH. Before starting testosterone replacement in functional hypogonadism of obesity, it would be desirable to initiate lifestyle modification to ensure weight reduction. TRT should be coupled with the management of other comorbidities related to obesity in MOSH patients. Balancing the risks and benefits of TRT should be considered in every patient before and during long-term management. Competing Interests: Conflict-of-interest statement: The authors declare that they have no conflict of interest. (©The Author(s) 2024. Published by Baishideng Publishing Group Inc. All rights reserved.) |
| References: | Aging Male. 2011 Sep;14(3):168-75. (PMID: 21039324) Obes Surg. 2019 Jul;29(7):2115-2125. (PMID: 31065918) J Clin Med. 2023 Aug 17;12(16):. (PMID: 37629396) Endocrinol Nutr. 2011 Jan;58(1):3-8. (PMID: 21215713) JAMA. 2015 Aug 11;314(6):570-81. (PMID: 26262795) J Clin Endocrinol Metab. 2018 Jun 1;103(6):2167-2174. (PMID: 29618085) J Sex Med. 2014 Jun;11(6):1577-92. (PMID: 24697970) Clin Endocrinol (Oxf). 2018 Oct;89(4):459-469. (PMID: 29855071) Clin Endocrinol (Oxf). 2013 Mar;78(3):330-7. (PMID: 23121123) Obes Rev. 2009 Mar;10(2):154-67. (PMID: 19021872) Surg Obes Relat Dis. 2022 Dec;18(12):1345-1356. (PMID: 36280539) PLoS One. 2014 Jan 29;9(1):e85805. (PMID: 24489673) Eur Endocrinol. 2019 Aug;15(2):83-90. (PMID: 31616498) Eur Urol. 2017 Dec;72(6):1000-1011. (PMID: 28434676) Drug Des Devel Ther. 2017 Mar 21;11:923-937. (PMID: 28356718) Metabolism. 1992 Mar;41(3):278-84. (PMID: 1542267) J Am Heart Assoc. 2013 Jul 10;2(4):e000271. (PMID: 23842280) J Androl. 1992 Jul-Aug;13(4):297-304. (PMID: 1399830) Front Endocrinol (Lausanne). 2021 Dec 24;12:813067. (PMID: 35002984) Int J Endocrinol. 2016;2016:1416503. (PMID: 27725831) Endocr Connect. 2019 Mar 1;8(3):195-202. (PMID: 30707677) J Sex Med. 2017 Dec;14(12):1504-1523. (PMID: 29198507) World J Mens Health. 2023 Jul;41(3):508-537. (PMID: 36876744) J Endocrinol. 2013 Apr 29;217(3):R25-45. (PMID: 23378050) Hypertension. 2001 May;37(5):1199-208. (PMID: 11358929) J Am Geriatr Soc. 2006 Nov;54(11):1666-73. (PMID: 17087692) Endocrine. 2023 Feb;79(2):273-282. (PMID: 36149528) Thromb Haemost. 2014 Aug;112(2):255-63. (PMID: 24695909) Endocr Rev. 2018 Jun 1;39(3):369-386. (PMID: 29522088) JAMA. 2008 Jan 2;299(1):39-52. (PMID: 18167405) Diabetes Care. 2014 Aug;37(8):2098-107. (PMID: 24804695) J Clin Endocrinol Metab. 2012 Jun;97(6):2050-8. (PMID: 22496507) Biochem Biophys Res Commun. 2004 May 28;318(2):503-6. (PMID: 15120629) Asian J Androl. 2016 Jan-Feb;18(1):25-34. (PMID: 25761833) Diabetes Care. 2011 Apr;34(4):828-37. (PMID: 21386088) J Clin Med. 2022 Aug 31;11(17):. (PMID: 36079056) Mol Cell Endocrinol. 2018 Jan 15;460:14-23. (PMID: 28606867) J Sex Med. 2010 Nov;7(11):3765-74. (PMID: 20807330) BMC Med. 2014 Nov 27;12:211. (PMID: 25428524) Obes Facts. 2022;15(2):228-239. (PMID: 34923493) Diabetes Care. 2003 Jun;26(6):1929-31. (PMID: 12766137) Clin Endocrinol (Oxf). 2005 Sep;63(3):280-93. (PMID: 16117815) J Am Geriatr Soc. 2002 Apr;50(4):707-12. (PMID: 11982672) Lancet Diabetes Endocrinol. 2021 Aug;9(8):484-490. (PMID: 34153269) Sex Med Rev. 2021 Jul;9(3):381-392. (PMID: 33933392) Clin Endocrinol (Oxf). 2015 Sep;83(3):344-51. (PMID: 25557752) BMC Med. 2016 Oct 7;14(1):153. (PMID: 27716209) Arch Gen Psychiatry. 2000 Feb;57(2):141-7; discussion 155-6. (PMID: 10665616) Asian J Androl. 2023 May-Jun;25(3):331-338. (PMID: 35848706) Diabetes Care. 2005 Jul;28(7):1636-42. (PMID: 15983313) PLoS One. 2016 Sep 01;11(9):e0161297. (PMID: 27584019) J Sex Med. 2008 May;5(5):1097-1113. (PMID: 18331266) Curr Urol. 2019 Oct;13(2):101-106. (PMID: 31768177) Fertil Steril. 1996 Apr;65(4):821-9. (PMID: 8654646) J Urol. 2016 Mar;195(3):699-705. (PMID: 26498057) JAMA. 2018 Sep 18;320(11):1163-1171. (PMID: 30326502) Int J Endocrinol. 2014;2014:527470. (PMID: 24688542) J Clin Endocrinol Metab. 2024 Jan 18;109(2):569-580. (PMID: 37589949) J Endocrinol Invest. 2016 Sep;39(9):967-81. (PMID: 27241317) Int J Endocrinol. 2021 Jun 04;2021:8799537. (PMID: 34149839) Circulation. 1999 Apr 6;99(13):1666-70. (PMID: 10190874) Int J Androl. 2011 Dec;34(6 Pt 1):528-40. (PMID: 20969599) N Engl J Med. 2010 Jul 8;363(2):109-22. (PMID: 20592293) J Clin Endocrinol Metab. 2018 May 1;103(5):1715-1744. (PMID: 29562364) Andrology. 2015 Nov;3(6):1094-103. (PMID: 26447645) Am Heart J. 2020 Jun;224:65-76. (PMID: 32335402) Am J Physiol Endocrinol Metab. 2001 Dec;281(6):E1172-81. (PMID: 11701431) Age (Dordr). 2015 Feb;37(1):9742. (PMID: 25637335) Age Ageing. 2022 Apr 1;51(4):. (PMID: 35429269) Ann Intern Med. 2022 May;175(5):665-673. (PMID: 35344380) Proc Natl Acad Sci U S A. 2001 Mar 13;98(6):3589-93. (PMID: 11248122) Heart. 2011 Jun;97(11):870-5. (PMID: 21177660) Endocr Rev. 2020 May 1;41(3):. (PMID: 32128581) Nutr Metab Cardiovasc Dis. 2008 May;18(4):256-62. (PMID: 17560771) J Clin Endocrinol Metab. 2011 Oct;96(10):3007-19. (PMID: 21816776) Mayo Clin Proc. 2007 Jan;82(1):29-39. (PMID: 17285783) Andrology. 2014 Nov;2(6):794-808. (PMID: 25271205) JAMA. 2013 Nov 6;310(17):1829-36. (PMID: 24193080) Obes Surg. 2023 Jun;33(6):1652-1658. (PMID: 37086370) Eur J Endocrinol. 2016 Mar;174(3):R99-116. (PMID: 26537862) Obesity (Silver Spring). 2013 Oct;21(10):1975-81. (PMID: 23512691) N Engl J Med. 2023 Jul 13;389(2):107-117. (PMID: 37326322) JAMA Netw Open. 2023 Oct 2;6(10):e2340030. (PMID: 37889486) Hum Reprod. 2012 Nov;27(11):3304-14. (PMID: 22811314) Andrology. 2020 Sep;8(5):970-987. (PMID: 32026626) Asian J Androl. 2014 Mar-Apr;16(2):223-31. (PMID: 24407187) J Clin Endocrinol Metab. 2010 Feb;95(2):639-50. (PMID: 20061435) Lancet Diabetes Endocrinol. 2021 Jan;9(1):32-45. (PMID: 33338415) J Clin Endocrinol Metab. 2005 Feb;90(2):678-88. (PMID: 15562020) Obes Rev. 2017 Jul;18(7):715-723. (PMID: 28489290) Ann N Y Acad Sci. 1968 Mar 29;149(1):366-76. (PMID: 5240723) Obes Facts. 2019;12(1):40-66. (PMID: 30673677) JAMA Intern Med. 2024 Apr 1;184(4):353-362. (PMID: 38315466) J Clin Psychiatry. 2001 Jun;62(6):406-12. (PMID: 11465516) J Sex Med. 2014 Mar;11(3):840-56. (PMID: 24308723) Endocr Rev. 2024 Mar 4;45(2):171-189. (PMID: 37559411) Mol Cell Endocrinol. 2015 Dec 15;418 Pt 2:120-33. (PMID: 26143633) Andrology. 2020 Nov;8(6):1590-1597. (PMID: 31696669) Diabet Med. 2024 Jan;41(1):e15217. (PMID: 37669131) J Clin Endocrinol Metab. 2010 Jun;95(6):2560-75. (PMID: 20525906) Obes Res Clin Pract. 2014 Jul-Aug;8(4):e339-49. (PMID: 25091355) BJU Int. 2006 Jul;98(1):116-24. (PMID: 16831155) Best Pract Res Clin Endocrinol Metab. 2022 Sep;36(5):101686. (PMID: 35981955) Prog Cardiovasc Dis. 1995 Nov-Dec;38(3):255-71. (PMID: 7494886) N Engl J Med. 2013 Sep 12;369(11):1011-22. (PMID: 24024838) Steroids. 2016 Nov;115:62-66. (PMID: 27543675) Basic Clin Androl. 2016 Jun 22;26:7. (PMID: 27340554) Clin Endocrinol (Oxf). 2016 Nov;85(5):772-780. (PMID: 27292585) J Endocrinol Invest. 2022 Dec;45(12):2385-2403. (PMID: 36018454) Clin Exp Hypertens A. 1992;14(3):367-75. (PMID: 1600637) |
| فهرسة مساهمة: | Keywords: Androgen therapy; Cardiovascular benefits; Male obesity-related secondary hypogonadism; Obesity; Testosterone replacement therapy |
| تواريخ الأحداث: | Date Created: 20240701 Latest Revision: 20240702 |
| رمز التحديث: | 20240702 |
| مُعرف محوري في PubMed: | PMC11212738 |
| DOI: | 10.5493/wjem.v14.i2.93689 |
| PMID: | 38948417 |
| قاعدة البيانات: | MEDLINE |
| تدمد: | 2220-315X |
|---|---|
| DOI: | 10.5493/wjem.v14.i2.93689 |